INTRODUCTION
Pulmonary artery hypertension (PH) occurring as an idiopathic condition or associated with an underlying disease is an unexplained disorder whose severe forms in adults and neonates are fatal and for which no satisfactory treatment is available. Hyperplasia of pulmonary-artery smooth muscle cells (PA-SMCs) is the primary determinant of the pulmonary vessel remodeling process that underlies PH 1 . Similarities exist between cancer and PH. Thus, cultured PA-SMCs and pulmonary-artery endothelial cells (PA-ECs) from patients with PH show growth dysregulation 2-5 , PA-SMCs from patients with PH have decreased susceptibility to apoptosis 6 , remodeled pulmonary vessels express cancer biomarkers 7 , and drugs designed to treat malignant proliferations exert beneficial effects in animal models of PH 8 .
One common abnormality in cancer is an inactivating mutation in the gene encoding the powerful growth-suppressive and proapoptotic transcription factor p53 9 . Also common is posttranslational p53 inactivation via interaction of the p53 protein with its negative regulator MDM2 (murine double minute 2), a specific p53 ubiquitin ligase and transcriptional inhibitor 10, 11 . MDM2 is overexpressed in many human tumors, suggesting that p53-MDM2
interactions may hold promise as a target for cancer therapy 12 . Nutlins are cis-imidazoline analogs recently developed as anticancer agents 13 . These selective small-molecule p53-MDM2 binding inhibitors stabilize p53, thereby increasing the expression of genes targeted by p53 including the antiproliferative gene BTG2, the prosenescent gene p21, and the proapoptotic genes Bax and PUMA 14 . The most potent Nutlin, Nutlin-3a, exhibits antitumor activity via p53 activation in various cancer cells and induces tumor regression when administered chronically to mice 13 . Nutlin-3a is being tested for the treatment of lymphoblastic leukemia in humans 15 .
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Treatments that activate p53 in PA-SMCs might be capable of limiting or reversing the pulmonary vascular remodeling process that characterizes PH. The ability of Nutlin-3a to stabilize and activate p53 in target cells depends on the expression and/or activity of MDM2 in these cells. MDM2 dysregulation has been reported in SMCs at sites of vascular injury 16 , as well as in human atherosclerotic tissues and in vascular SMCs from patients with primary aldosteronism 17, 18 . Moreover, MDM2 expression can be induced by hypoxia or by p53 11, 19 .
Whether MDM2 expression or activity is altered during progression of hypoxic or nonhypoxic PH remains unexplored. The potential effects of p53 activation in target cells may also vary according to cell status or environmental conditions, leading to cell quiescence, senescence, or apoptosis [20] [21] [22] [23] . Both senescence and apoptosis of PA-SMCs may provide therapeutic benefits in PH, although the accumulation of senescent cells within the vessel wall may potentially affect the remodeling process 24 . Until now, prosenescence therapy for PH has not been evaluated.
In the present study, we tested the hypothesis that Nutlins hold therapeutic potential in PH via prosenescence effects. To this end, we first examined the effects of Nutlin-3a on cultured human PA-SMCs. Second, we investigated the effects of chronic Nutlin-3a treatment in normoxic mice free of PH; mice with hypoxia-induced PH; chronically hypoxic mice simultaneously treated with SU5416 (SU5416/hypoxia) 25 ; and transgenic mice overexpressing the serotonin transporter in SMCs (SM22-5HTT+ mice), which develop spontaneous PH in normoxia 26 . Finally, we examined the mechanisms of action of Nutlin-3a by investigating p53 and p21 knockout mice exposed to chronic hypoxia. were produced and bred as previously described 26 . These SM22-5HTT+ mice are fertile and have a normal life span and normal growth 5 . Mice with deletion of the p53 (p53
) gene were obtained from Jackson Laboratory (Bar Harbor, ME). Only male mice were used for the experiments. Nutlin-3a was administered by intraperitoneal injection in a dosage of 6, 12, or 25 mg/Kg/day. At treatment completion, the lungs were removed and prepared for histological or Western-blot analyses.
Exposure to chronic hypoxia
Male mice aged 15-20 weeks were exposed to chronic hypoxia (9% O 2 ) in a ventilated chamber (Biospherix, New York, NY) 27 . To establish the hypoxic environment, the chamber was flushed with a mixture of room air and nitrogen. The chamber was opened every other day for 1 hour to clean the cages, administer drugs, and replenish food and water supplies.
Normoxic mice were kept in the same room, with the same light-dark cycle. Mice subjected to SU5416/hypoxia received an intraperitoneal injection of SU5416 20 mg/Kg once a week during a 3-week period of hypoxia exposure 25 .
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We anesthetized mice previously exposed to hypoxia, room air, or SU5416/hypoxia; as well as SM22-5HTT+ mice. After incision of the abdomen, a 26-gauge needle connected to a pressure transducer was inserted into the right ventricle through the diaphragm, and right ventricular systolic pressure (RVSP) was recorded immediately. Then, the thorax was opened and the lungs and heart were removed. The right ventricle (RV) was dissected from the left ventricle plus septum (LV+S), and these dissected samples were weighed for determination of Fulton's index (RV/LV+S). The lungs were fixed by intratracheal infusion of 4% aqueous buffered formalin. A midsagittal slice of the right lung was processed for paraffin embedding.
Sections 5 µm in thickness were cut and stained with hematoxylin-phloxine-saffron for examination by light microscopy. In each mouse, a total of 20 to 30 intraacinar vessels accompanying either alveolar ducts or alveoli were examined by an observer who was blinded to the treatment or genotype. Each vessel was categorized as nonmuscular (no evidence of vessel wall muscularization) or muscular, i.e., partially muscular (SMCs identifiable in less than three-fourths of the vessel circumference) or fully muscular (SMCs in more than threefourths of the vessel circumference). The percentage of muscularized pulmonary vessels was determined by dividing the number of partially or fully muscular vessels by the total number of vessels in the relevant group of animals. In addition, medial wall thickness of fully muscularized intraacinar arteries was calculated in SU5416/hypoxia mice and expressed as follows: index (%)=(external diameter -internal diameter)/external diameter·100. Cell proliferation (Ki67-stained cells), apoptosis (TUNEL-positive cells), and senescence (p21-stained cells) were assessed in the walls of distal pulmonary vessels and expressed as the number of stained nuclei over the total number of nuclei counted in the media of at least 20 muscularized vessels per mouse.
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Echocardiography Closed-chest transthoracic echocardiography was performed in nonsedated mice as described in the expanded methods section available in the Online Supplement. Images were acquired using a 13-MHz linear-array transducer with a digital ultrasound system (Vivid 7, GE Medical Systems). All measures were averaged on 5 cardiac cycles, and the reader was blinded to treatment group.
Studies on cultured human pulmonary artery smooth muscle cells (PA-SMCs)
Cultured PA-SMCs were collected from pulmonary arteries of patients undergoing lung surgery for localized lung tumors 24 . To assess the effects of Nutlin-3a on PA-SMC proliferation, we exposed PA-SMCs to Nutlin-3a (2.5-10 µM) or vehicle in serum-free medium then added platelet-derived growth factor-BB (PDGF-BB, 50 ng/mL). After 48 hours, tetrazolium salt (MTT, Sigma, Lyon, France) was added to each well (0.2 mg/mL).
After 4 hours' incubation at 37°C, the culture medium was removed and formazan crystals were solubilized by adding 500 L of DMSO. Tetrazolium salt reduction to formazan within the cells was quantified by spectrophotometry at 520 nm and taken as an indicator of the number of cells.
To assess the effects of Nutlin-3a on PA-SMC apoptosis, cells were trypsinized and In addition, cell transfection studies were performed using a p53 Cignal Reporter Assay (Qiagen, ZA Courtaboeuf, France) for assessing p53 signaling in response to Nutlin, as described in the online supplement. 
Statistical analysis
The data are described as mean±SEM. Parametric tests were used after verification that the variables in each group were normally distributed. One-way analysis of variance (ANOVA) was performed to compare treatment effects with the three Nutlin-3a doses and the vehicle.
When a significant difference was found, group means were compared using the modified t test. P values lower than 0.05 were considered significant.
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RESULTS
Effects of Nutlin-3a treatment on cultured human PA-SMCs
Nutlin-3a treatment of cultured human PA-SMCs was followed by a marked rise in phosphorylated p53 protein levels within 2 hours after treatment, with a peak after 4 hours and persistent elevation until 24 hours ( Figure 1A) ; total p53 protein and p53 mRNA levels remained unchanged ( Figure 1A ). Nutlin-3a treatment also induced marked but delayed increases in p21 mRNA and protein levels, which peaked at 24 hours ( Figure Table I ). Nutlin-3a, 12 mg/Kg/d, from day 15 to day 30 partially reversed PH in chronically hypoxic mice ( Figure 2C ).
Nutlin-3a treatment markedly increased lung levels of p53, p21, and MDM2 protein and of p21, Bax, Bcl2, and BTG2 mRNAs in chronically hypoxic mice but not in normoxic animals ( Figures 3A and 3D ). Phosphorylated p53 protein levels measured in whole lung proteins and total p53 protein levels measured in the nuclear and cytoplasmic fractions of lung proteins increased after Nutlin-3a treatment in hypoxic but not normoxic mice ( Figure 3B 3C ).
Because lung samples were collected exactly 3 hours after the last Nutlin-3a injection in both normoxic and hypoxic mice, the dissimilar response to Nutlin-3a in hypoxic and normoxic mice was interpreted as reflecting increased MDM2 activity during hypoxia. This increased MDM2 activity was measured, although total lung MDM2 protein levels did not change from normoxia to hypoxia ( Figure 3A ). In contrast to the dose-dependent increase in lung p21, Bax, Bcl2, and BTG2 mRNA levels induced by Nutlin-3a, lung expression of the proapoptotic gene PUMA, which increased from normoxia to hypoxia, was reduced by
Nutlin-3a treatment ( Figure 3D ). The increased p53 protein levels induced by Nutlin-3a also occurred in the kidneys, heart, spleen, and liver from normoxic and hypoxic mice, although at different levels (online Figure 1) . A marked (3.5-fold) increase in p53 protein was observed only in the lungs and kidneys of chronically hypoxic mice. To assess the effects of Nutlin-3a in a third model of PH characterized by more intense pulmonary vascular remodeling, we investigated mice subjected to SU5416/hypoxia 25 .
Effects of Nutlin-3a treatment in SM22-
Treatment with 12 mg/Kg/d during 3 weeks partially prevented PH in SU5416/hypoxia mice, inducing a substantial increase in p21-stained cell counts and marked attenuation of the increased wall thickness of pulmonary vessels (online Figure 3A and 3B). MDM2 protein levels, which were higher in SU5416/hypoxia mice than in wild-type mice, increased further in response to Nutlin-3a (Online Figure 3C ). 
Immunolocalization of MDM2 in lung tissues
Effects of treatment with Nutlin-3a in p53 -/-mice
To determine whether Nutlin-3a effects required p53 stabilization, we investigated p53 -/-mice and their littermate controls during exposure to chronic hypoxia. Nutlin-3a in a dose of 12 mg/Kg/day did not prevent hypoxic PH in p53 -/-mice, in contrast to its protective effect in control nonmutant mice ( Figure 7A ). Nutlin-3a treatment also failed to alter p53 downstream signaling in these mice, indicating clearly that p53 was required to mediate Nutlin-3a effects
(Figures 7B and online Figure 4 ). Interestingly, PH was slightly but significantly more severe in p53 -/-mice than in control wild-type mice, in accordance with previously published studies 28 .
Effects of treatment with Nutlin-3a in p21 -/-mice
To determine whether p21 was required to prevent PH in chronically hypoxic mice, we investigated the effects of Nutlin-3a treatment in p21 -/-mice. As shown in Figure 8 , Nutlin-3a treatment failed to protect hypoxia-exposed p21 -/-mice against PH. Interestingly, the ability of Nutlin-3a treatment to enhance Bax and BTG2 expression was reduced but not abrogated in p21 -/-mice, whereas Nutlin-3a-induced changes in Bcl2 and PUMA expression were inserm-00829264, version 1 -3 Jun 2013
abolished (online Figure 5) . In p21 -/-mice, PH was slightly but significantly more severe than in wild-type controls, suggesting that p21-induced cell senescence not only was critical in mediating Nutlin-3a effects, but also played a role in the development of hypoxic PH.
inserm-00829264, version 1 -3 Jun 2013
DISCUSSION
The main finding of the present study is that Nutlin-3a, a potent and selective antagonist of the p53-MDM2 interaction, induces PA-SMC senescence in vitro and attenuates or reverses PH in three distinct experimental mouse models, decreasing the number of proliferating PASMCs and increasing the number of p21-stained senescent cells. Nutlin-3a led to marked increases in lung p53 protein and p53 downstream gene expression in mice with PH, whereas only minor effects were noted in control mice without PH. These results are consistent with potentiation of Nutlin-3a effects in PH due to increased MDM2 activity. The ability of Nutlin3a to prevent or reverse PH required lung p53 stabilization and increased p21 expression, as indicated by the inability of Nutlin-3a to prevent chronic hypoxia-induced PH in p53 -/-and p21 -/-mice. Thus, Nutlin-3a holds promise as a prosenescence treatment targeting PA-SMCs during PH progression.
The induction of cell senescence is a novel therapeutic approach to malignant and nonmalignant proliferative disorders 29 . Inducing PA-SMC senescence is expected to be more efficient than inducing cell quiescence in PH, as cell growth arrest in senescence is stable and largely irreversible. Here, we found that Nutlin-3a treatment of human PA-SMCs led to a large increase in phosphorylated p53 protein levels, with a subsequent increase in p21 expression and acquisition of a typical senescence phenotype characterized by increased size, a flat shape, and -gal staining. This senescence-induced growth arrest appeared irreversible, since Nutlin-3a removal did not restore PA-SMC proliferation. However, PA-SMCs treated with Nutlin-3a did not become apoptotic, a finding consistent with results obtained using other cell types, including fibroblasts from mice and humans 20, 21 .
Chronic Nutlin-3a treatment of mice during hypoxia exposure considerably attenuated PH severity by decreasing distal pulmonary artery muscularization. This effect was doseinserm-00829264, version 1 -3 Jun 2013 dependent, and no toxic effects were detected even at the highest dose tested. Nutlin-3a treatment for 3 weeks also attenuated PH in mice subjected to SU5416/hypoxia and partially reversed established PH in SM22-5HTT+ mice and in chronically hypoxic mice, producing similar decreases in pulmonary vessel muscularization. These effects of Nutlin-3a were associated with a marked reduction in Ki67-positive dividing PA-SMCs, together with an increased number of p21-stained PA-SMCs, but with no increase in apoptotic TUNELpositive cells. Taken together with our in vitro data, these results indicate that prevention or reversal of pulmonary vessel remodeling in our mouse models of PH resulted from the induction of PA-SMC senescence by Nutlin-3a.
We found that the number of p21-stained senescent cells following Nutlin-3a treatment increased to a much greater extent in lungs from chronically hypoxic and SM22-5HTT+ mice than from their respective controls without PH, suggesting potentiation of Nutlin-3a effects during PH. One potential advantage of using Nutlin to treat cancer is that cancer cells overexpress MDM2 and should therefore prove more susceptible than normal cells to growth arrest in response to Nutlin 12, 23 . The results of the present study also suggest greater susceptibility to Nutlin-3a of proliferating PA-SMCs in PH, compared to PA-SMCs from control animals. Nutlin-3a administration was followed by considerably larger increases in lung p53 protein levels in chronically hypoxic mice and SM22-5HTT+ normoxic mice than in their respective controls. These effects were related to increased MDM2 activity in chronically hypoxic mice and to increased MDM2 activity and expression in SM22-5HTT+
mice. Potentiation of Nutlin-3a effects during PH was also supported by the Nutlin-3a-induced expression of p53 downstream genes including p21, Bax, Bcl2, BTG2, and MDM2, which was far greater in hypoxic and SM22-5HTT+ mice than in control mice without PH.
Moreover, MDM2 was strongly expressed by PA-SMCs in remodeled vessels from inserm-00829264, version 1 -3 Jun 2013 chronically hypoxic mice, from SM22-5HTT+ mice, and from mice subjected to SUGEN/hypoxia compared to those from mice without PH. PA-SMCs from remodeled pulmonary vessels of patients with chronic lung disease also exhibited increased MDM2 immunostaining compared to those from nonremodeled vessels of the same patients. Taken together, these results indicate that prevention or reversal of pulmonary vessel remodeling in these mouse models of PH was due to the induction of PA-SMC senescence and that the effects of Nutlin-3a on PA-SMCs were potentiated during PH, probably because of activation and/or overexpression of the Nutlin-3a target MDM2 protein. Thus, Nutlin-3a holds promise as a targeted treatment for PH.
Of note, we found that Nutlin-3a treatment increased both phosphorylated and nonphosphorylated p53 protein in lungs from hypoxic mice but increased only phosphorylated p53 protein in cultured human PA-SMCs. Neither phosphorylated nor total p53 protein was altered by Nutlin-3a in lungs from normoxic mice. These results are consistent with data suggesting that Nutlin-3a efficacy may vary according to basal MDM2 activity and conditions of Nutlin-3a treatment 29, 30 . Moreover they emphasize the complexity of the interactions between MDM2 and p53. Indeed, the MDM2-p53 complex is known to form primarily in the nucleus and to shuttle subsequently from the nucleus to the cytoplasm, where MDM2 targets p53 for degradation by acting as an ubiquitin-ligase 30 . The dissimilar effects of Nutlin-3a in hypoxic versus normoxic mice are also consistent with previous studies showing that systemic Nutlin treatment is toxic to tumor tissue but not to normal tissue 31, 32 .
In both normoxic and hypoxic mice treated with Nutlin-3a, we observed minimal changes in p53 protein levels in the heart, spleen, and liver and found that cardiac function remained Although p53 regulation appears to be the central focus of MDM2 activity, the p53-binding domain of MDM2 binds to other proteins that are potentially involved in cell growth and survival 34 . To investigate whether Nutlin-3a effects were mediated solely by stabilization and overexpression of p53, we investigated p53 -/-mice. Nutlin-3a did not prevent PH in p53 -/-mice simultaneously exposed to chronic hypoxia. Neither did Nutlin-3a alter p53 downstream signaling in these mice, clearly indicating that p53 was required to mediate the effects of Nutlin-3a. Another point of interest was whether p53 played a pivotal role in PH development in our mouse models. As previously reported, we found that PH was more severe in p53
-/-mice than in control wild-type mice 28 . However, in contrast to these previous studies showing marked increases in lung p53 protein levels from normoxia to hypoxia 28 , we observed only minimal alterations in baseline p53 levels in hypoxic vs. normoxic mice and in SM22-5HTT+ mice vs. control wild-type mice. The reason for this difference is unclear but probably involves differences in hypoxia exposure conditions. The relative stability of p53 protein levels from normoxia to hypoxia in our study is probably ascribable to increased p53 protein degradation due to increased MDM2 ubiquitin ligase activity. Suppression of this adaptive response by Nutlin-3a led to major increases in p53 in PA-SMCs, thereby strongly inhibiting the pulmonary vascular remodeling process.
Among the transcriptional targets of p53, p21 has been shown to play a major role as a regulator of cell-cycle progression and to be involved in cell senescence 35 . We found that the protective action of Nutlin-3a against PH required p21, as indicated by the inability of Nutlin3a to prevent chronic hypoxia-induced PH in p21 -/-mice, despite significant increases in mRNA levels of the antiproliferative protein BTG2 and of the proapoptotic protein Bax.
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These results indicate a prominent role for p21 in our experimental PH model and support cell-senescence induction as the mechanism by which Nutlin-3a protects against PH.
Moreover, the slight increase in PH severity noted in p21 -/-mice compared to their hypoxic controls suggests involvement of p21 in the control of hypoxic PH progression.
The present results supporting a beneficial effect of cell-senescence induction in PH may appear to contradict our previous studies supporting a role for senescent cells in Further studies are therefore needed to identify the mechanisms responsible for senescent-cell clearance in PH. Whether prosenescence strategies such as Nutlin therapy hold promise for the treatment of PH will need to be evaluated.
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